Agenus provides corporate update and first quarter 2023 financial results

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023. "with over 350 patients dosed with botensilimab in our phase 1 study, we have demonstrated 20-50% response rates in 9 solid tumor cancers. these results suggest that botensilimab could provide significant benefit to patients who have no.
AGEN Ratings Summary
AGEN Quant Ranking